ArticleBehavioural brain research2015
NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism.
Article in Behavioural brain research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder.CNS drugs · 2024Review
- GluN2A mediates ketamine-induced rapid antidepressant-like responses.Nature neuroscience · 2023Article
- The effects of physical activity on glutamate neurotransmission in neuropsychiatric disorders.Frontiers in sports and active living · 2023Review
- Traxoprodil Produces Antidepressant-Like Behaviors in Chronic Unpredictable Mild Stress Mice through BDNF/ERK/CREB and AKT/FOXO/Bim Signaling Pathway.Oxidative medicine and cellular longevity · 2023Article
- Update on GPCR-based targets for the development of novel antidepressants.Molecular psychiatry · 2022Review
- Structural connectivity and subcellular changes after antidepressant doses of ketamine and Ro 25-6981 in the rat: an MRI and immuno-labeling study.Brain structure & function · 2021Article
- Ketamine: Neuroprotective or Neurotoxic?Frontiers in neuroscience · 2021Review
- Synaptotagmin-7 deficiency induces mania-like behavioral abnormalities through attenuating GluN2B activity.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Rislenemdaz treatment in the lateral habenula improves despair-like behavior in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- Extrasynaptic CaMKIIα is involved in the antidepressant effects of ketamine by downregulating GluN2B receptors in an LPS-induced depression model.Journal of neuroinflammation · 2020Article
- NMDAR modulators as rapid antidepressants: Converging and distinct signaling mechanisms.Integrative clinical medicine · 2020Article
- Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.Annual review of pharmacology and toxicology · 2019Review
- NMDA receptor GluN2A subunit deletion protects against dependence-like ethanol drinking.Behavioural brain research · 2018Article
- Ketamine administration during a critical period after forced ethanol abstinence inhibits the development of time-dependent affective disturbances.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
- The Neurogenesis Actuator and NR2B/NMDA Receptor Antagonist Ro25-6981 Consistently Improves Spatial Memory Retraining Via Brain Region-Specific Gene Expression.Journal of molecular neuroscience : MN · 2018Article
- Mechanisms of ketamine action as an antidepressant.Molecular psychiatry · 2018Review
- Uncoupling DAPK1 from NMDA receptor GluN2B subunit exerts rapid antidepressant-like effects.Molecular psychiatry · 2018Article
- Convergent Mechanisms Underlying Rapid Antidepressant Action.CNS drugs · 2018Review
- EphB2 Deficiency Induces Depression-Like Behaviors and Memory Impairment: Involvement of NMDA 2B Receptor Dependent Signaling.Frontiers in pharmacology · 2018Article
- Gender-Related Hippocampal Proteomics Study from Young Rats After Chronic Unpredicted Mild Stress Exposure.Molecular neurobiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 5 countries.
Funding
Abstract
Drugs targeting the glutamate N-methyl-d-aspartate receptor (NMDAR) may be efficacious for treating mood disorders, as exemplified by the rapid antidepressant effects produced by single administration of the NMDAR antagonist ketamine. Though the precise mechanisms underlying the antidepressant-related effects of NMDAR antagonism remain unclear, recent studies implicate specific NMDAR subunits, including GluN2A and GluN2B, as well as the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor (AMPAR) subunit glutamate receptor interacting molecule, PSD-95. Here, integrating mutant and pharmacological in mice, we investigated the contribution of these subunits and molecules to antidepressant-related behaviors and the antidepressant-related effects of the GluN2B blocker, Ro 25-6981. We found that global deletion of GluA1 or PSD-95 reduced forced swim test (FST) immobility, mimicking the antidepressant-related effect produced by systemically administered Ro 25-6981 in C57BL/6J mice. Moreover, the FST antidepressant-like effects of systemic Ro 25-6981 were intact in mutants with global GluA1 deletion or GluN1 deletion in forebrain interneurons, but were absent in mutants constitutively lacking GluN2A or PSD-95. Next, we found that microinfusing Ro 25-6981 into the medial prefrontal cortex (mPFC), but not basolateral amygdala, of C57BL/6J mice was sufficient to produce an antidepressant-like effect. Together, these findings extend and refine current understanding of the mechanisms mediating antidepressant-like effects produced by NMDAR-GluN2B antagonists, and may inform the development of a novel class of medications for treating depression that target the GluN2B subtype of NMDAR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.